Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Doctors Are Slow to Address Cardiovascular Risk Factors In Type 2 Diabetes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Elaine W.
Received at customerservice @ ezorbonline.com Tuesday, March 2, 2021, 9:26 AM PST
(Unedited)

I have stenosis of the upper spine, use to have sciatica nerve problems.

I have taken EZORB for some years now, don’t think I would be walking now if I didn’t take it. I’m 83 now and and walk any where I want to.

Sent from my iPad Elaine w.

Letter II: From Lindsey P., Fort Worth TX
Recorded at Testimonial Submit Form Thursday, January 21, 2020 at 15:53:06
(Unedited)

Hi my name is Lindsey P. I'm 67 year young and I've been using Marvlix for 7 months.

I looked up Marvlix when my GFR dropped to 51. I read all the testimonials and decided to give it a try. I'm retired but I'm very active in my church. I don't want to end up in dialysis.

I took 8 Marvlix daily faithfully for 6 months. My latest kidney report shows GFR of 63. I can't thank you enough for making this wonderful product available. I'll continue with 6 a day for the rest of my life.

Best regard,
Lindsey P. Fort Worth, TX

This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.

People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular (CV) risk factors, even if they are in a high-risk category, research shows.

“This resulted in very high probability of clinically unacceptable blood pressure and lipid burden during disease progression at population level,” say Sanjoy Paul (University of Melbourne, Victoria, Australia) and study co-authors.

As reported in Diabetes, Obesity and Metabolism, the team identified 254,925 people with type 2 diabetes in the UK’s THIN primary care database.

At the point of diagnosis, 66% of the cohort overall had dyslipidemia, the same proportion had hypertension, and 46% had both risk factors. The prevalence in people younger than 50 years was 60% for dyslipidemia, 42% for hypertension, and 29% for both.

However, the team notes that the prevalence of dyslipidemia in the younger age group rose between study baseline in 2005 and 2016, whereas the rate of hypertension was relatively stable. Indeed, dyslipidemia prevalence rose in all age groups younger than 60 years.

Use of medications to control these risk factors increased between the point of diagnosis and 6 months later; however, people younger than 50 years were given these medications less often than older people were. For example, rates of lipid-lowering therapy among people with baseline dyslipidemia rose from 37% to 63% overall, but from 13% to 43% in the younger age group.

This was despite around 80% of the younger group being at high risk for atherosclerotic CV disease (ASCVD), defined as prevalent disease or at least two risk factors (smoking, obesity, hypertension and/or dyslipidemia, or microvascular disease).

Moreover, the median time to initiating medication among people not on it at baseline was only slightly less for high- versus low-risk people, at 10.8 versus 13.1 months for lipid-lowering therapy and 20.2 versus 22.2 months for antihypertensives.

And within the high-risk group, the time to initiating lipid-lowering or antihypertensive therapy was generally longer in younger people, with people younger than 40 years waiting a median of 20.4 months for lipid-lowering therapy and 28.1 months for antihypertensive therapy, compared with approximately 10 and 19 months, respectively, for the older age groups.

In line with these findings, people with dyslipidemia at baseline who did not start lipid-lowering therapy until a year or more later were 16-25% more likely than those who started sooner to have uncontrolled lipid levels over the following 2 years.

Likewise, people with hypertension who had a delayed start to antihypertensive medication had a 40-59% increased risk for continued uncontrolled blood pressure.

“It is particularly important to note here that those who are deemed to have low ASCVD risk at diagnosis and initiating therapy after one year in fact had higher probability of risk factor control failure compared with those who were deemed to have high ASCVD risk at baseline and initiating the therapy within one year of diagnosis,” say the researchers.

“This unique finding is reflected across all age groups,” they add, and suggest that current guidelines on risk stratification and pharmacologic intervention may need to be revised.

Original research was published in Diabetes Obes Metab 2021; doi:10.1111/dom.14364.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index